KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Price Stock Quantity  
USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

KU-55933 (ATM Kinase Inhibitor) Chemical Structure
Molecular Weight: 395.49

Validation & Quality Control

Cited by 35 publications:

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

KU-55933 (ATM Kinase Inhibitor) is available in the following compound libraries:

ATM/ATR Inhibitors with Unique Features

  • Pan ATM/ATR Inhibitor

    CGK 733 Dual ATM/ATR inhibitor, IC50=~200 nM.

  • Most Potent ATM/ATR Inhibitor

    AZ20 ATR, IC50=5 nM.

  • ATM/ATR Inhibitor in Clinical Trial

    BEZ235 (NVP-BEZ235, Dactolisib) Phase II for Advanced Endometrial Carcinoma.

  • Newest ATM/ATR Inhibitor

    VE-822 ATR inhibitor with IC50 of 19 nM.

Product Information

  • Compare ATM/ATR Inhibitors
    Compare ATM/ATR Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets ATM [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)

 View  More

IC50 12.9 nM 2.5 μM 9.3 μM 16.6 μM
In vitro KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
DU-145M3\XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLrWJp7UUN3ME2zMlI4OzV{IN88US=>M4XwWHNCVkeHUh?=
HuO-3N1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHPZlRSUUN3ME20MlE4OTR{IN88US=>NUfvTnlrW0GQR1XS
LAMA-84MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;xbVFKSzVyPUSuOVg1PjVizszNMVnTRW5ITVJ?
CAL-72NXTxN|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWK5PYdSUUN3ME21MlQ5ODh2IN88US=>M3;WcHNCVkeHUh?=
LoVoNGji[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPoTWM2OD14LkmzNlM6KM7:TR?=MX7TRW5ITVJ?
HHNEDoSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRThwMke2O|Eh|ryPNH;zU4lUSU6JRWK=
SK-MEL-3M3;zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLR[I9KSzVyPUiuNlg2PzVizszNMXrTRW5ITVJ?
KM12MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDOSpQ4UUN3ME25MlIyOTR{IN88US=>MXPTRW5ITVJ?
NCI-H1437MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\NdHNKSzVyPUmuPFA6PyEQvF2=MU\TRW5ITVJ?
NCI-H1838NVO2VG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTFzLkG4OlUh|ryPNGSxSlRUSU6JRWK=
J-RT3-T3-5MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnriTWM2OD1zMT6yOFE4KM7:TR?=NW\ENGtIW0GQR1XS
GOTOMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXienhKSzVyPUGxMlY6QTZizszNMnH5V2FPT0WU
LB2241-RCCNIfJV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjIb2FjUUN3ME2xNU44OTh4IN88US=>Ml7yV2FPT0WU
ES7M4PQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTFzLke4PEDPxE1?M3;Lc3NCVkeHUh?=
KP-N-YSM4DHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXv0UIJiUUN3ME2xNk43OzV2IN88US=>MnHsV2FPT0WU
CAL-12TMkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEG5OlNKSzVyPUGzMlYyPyEQvF2=M4nX[3NCVkeHUh?=
COLO-684MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHHTWM2OD1zND6xOVY6KM7:TR?=MWjTRW5ITVJ?
DOKM{TlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3Pd5JmUUN3ME2xOU4{OzJ7IN88US=>M2HBUXNCVkeHUh?=
Hs-578-TMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTF3LkSxPFIh|ryPM3zJXXNCVkeHUh?=
D-423MGM4H0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTxboZ{UUN3ME2xOU42OjN4IN88US=>MWfTRW5ITVJ?
DBTRG-05MGNEjoWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHldYg1UUN3ME2xOU43OTFzIN88US=>NYLkSlRTW0GQR1XS
VM-CUB-1MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTF3Lkm4OFkh|ryPMn7JV2FPT0WU
KG-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPLZWZTUUN3ME2xOk4xQTl4IN88US=>M3zxZnNCVkeHUh?=
8305CNVztSlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HtUGlEPTB;MU[uNVg5QSEQvF2=NWHWWo5{W0GQR1XS
HuH-7M2C3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPmRY1KSzVyPUG2MlI3PzRizszNNVTJXmpXW0GQR1XS
LXF-289NVPyfJNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnhTWM2OD1zNj6yO|Q4KM7:TR?=M12zOXNCVkeHUh?=
NCI-H1793MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrBeoxKSzVyPUG2MlQ4OTJizszNNGXB[4pUSU6JRWK=
ChaGo-K-1M1XOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPnTWM2OD1zNj62OVY5KM7:TR?=MUTTRW5ITVJ?
GCIYMoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fhUmlEPTB;MU[uO|kxPSEQvF2=M{\XSXNCVkeHUh?=
SK-MEL-28NHfZd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\qPVZIUUN3ME2xO{4xPDd3IN88US=>MkLLV2FPT0WU
NCI-SNU-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTF5LkGyOlkh|ryPMmm4V2FPT0WU
CTB-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jQXWlEPTB;MUeuNlI2QSEQvF2=NXrDZo5uW0GQR1XS
NCI-H82NITlZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfEVVdKSzVyPUG3MlQ2PzNizszNMl;nV2FPT0WU
HCC2998M13NS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF5Lk[3N|Mh|ryPMonIV2FPT0WU
NCI-H2030NYHmUplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjSW404UUN3ME2xPE4yQTl5IN88US=>NITjTHBUSU6JRWK=
HuP-T3MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTF6LkW4PFgh|ryPNIS5OWpUSU6JRWK=
697NX7scZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrhTXFKSzVyPUG5MlAzODFizszNNW\yUWVUW0GQR1XS
MLMANH;McWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTF7LkC1OVch|ryPMYrTRW5ITVJ?
HCC70M1\rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzxUHRKSzVyPUG5MlQ5QSEQvF2=NUT6WoJSW0GQR1XS
A704NGLTZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHf4XGxKSzVyPUG5Mlg{ODVizszNMVrTRW5ITVJ?
D-283MEDM2XZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;SdmVrUUN3ME2yNE42OzN7IN88US=>MVXTRW5ITVJ?
U031NUe2Om4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjQfYs6UUN3ME2yNU4yPDh7IN88US=>MULTRW5ITVJ?
HSC-3Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTJzLkG4N|Uh|ryPM3;HPXNCVkeHUh?=
JVM-3M1rOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HKfmlEPTB;MkKuOVA3KM7:TR?=NIH0OXlUSU6JRWK=
MewoMnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj6OW5IUUN3ME2yNk42ODd|IN88US=>NFLHblhUSU6JRWK=
YH-13MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ{LkWxNlMh|ryPMUnTRW5ITVJ?
LB1047-RCCNEHuco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTJ{LkW4O|kh|ryPNIHYO25USU6JRWK=
HCC2157MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XhW2lEPTB;MkKuPFA2PCEQvF2=MnrsV2FPT0WU
SNU-449MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJ{Lki3OFgh|ryPM3rnZXNCVkeHUh?=
Ramos-2G6-4C10M2fueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPJco5KSzVyPUKyMlk3KM7:TR?=MnrMV2FPT0WU
CHL-1Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJ|LkeyPVIh|ryPM3PRO3NCVkeHUh?=
SK-MEL-30MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mki0TWM2OD1{ND60OlYzKM7:TR?=MlGzV2FPT0WU
PANC-08-13MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3pTWM2OD1{NT6wPVM5KM7:TR?=NIH1V4VUSU6JRWK=
QIMR-WILMkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTJ3LkG4OVgh|ryPNUCzSHRLW0GQR1XS
BFTC-905MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ3LkW5OFQh|ryPM3PsfHNCVkeHUh?=
GI-1NUnwWHFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXwTWM2OD1{NT63NFU2KM7:TR?=NH65SZJUSU6JRWK=
MDA-MB-415Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnDXINKSzVyPUK2MlUxOzNizszNNH\MXXRUSU6JRWK=
GT3TKBNE\1R3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnVTWM2OD1{Nj61N|QzKM7:TR?=M2PjdnNCVkeHUh?=
DELMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJ4LkizOVYh|ryPNWO1T2U5W0GQR1XS
KOSC-2M1nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJ4LkmwO|Uh|ryPM{mzcnNCVkeHUh?=
RVH-421Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTVTWM2OD1{Nz6yPVIyKM7:TR?=M4rM[3NCVkeHUh?=
EW-13NHv2VIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorlTWM2OD1{Nz60N|A5KM7:TR?=Ml60V2FPT0WU
639-VNITTWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLwZolKSzVyPUK3MlUyOTlizszNMV;TRW5ITVJ?
A2780MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXVVpFKSzVyPUK3MlY1OSEQvF2=NVLuSGxTW0GQR1XS
SW982NUPvN|BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYO2foxbUUN3ME2yO{46ODV{IN88US=>MUDTRW5ITVJ?
SW1710MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nrN2lEPTB;MkiuNFk5OSEQvF2=NYDwS3JVW0GQR1XS
HCC1569MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTJ6LkS4PVch|ryPNIjtRZJUSU6JRWK=
MV-4-11NXrrbFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoexTWM2OD1{OD61O|M2KM7:TR?=NHjQSnVUSU6JRWK=
BHT-101NHS2c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvQ[mJXUUN3ME2yPE43PTd{IN88US=>NXXL[GFKW0GQR1XS
Ca9-22MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljPTWM2OD1{OD63NVQh|ryPNHjzPXlUSU6JRWK=
HAL-01NWPEbYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLKTWM2OD1{OD63OlE2KM7:TR?=NILYPYpUSU6JRWK=
D-263MGMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LZcGlEPTB;MkmuN|Q1KM7:TR?=MnTVV2FPT0WU
NEC8M4HQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnoTWM2OD1{OT61OVQ5KM7:TR?=NWLwZolNW0GQR1XS
EKVXNUfKdXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTNzLkW4OFch|ryPMnrDV2FPT0WU
EM-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTNzLk[zNFQh|ryPMnu1V2FPT0WU
MFM-223MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTrTWM2OD1|MT64NFk5KM7:TR?=NFXCdY5USU6JRWK=
SK-PN-DWMkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIqwOmFKSzVyPUOyMlE1ODZizszNNIKzPJlUSU6JRWK=
HuO9NXO4OIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEC5RY9KSzVyPUOyMlUzQDJizszNM4DGXXNCVkeHUh?=
MHH-PREB-1M4f0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTN{Lk[yN|Qh|ryPMnOyV2FPT0WU
OVCAR-4M4nC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoToTWM2OD1|Mj64N|Y{KM7:TR?=NYD4Sng5W0GQR1XS
NCI-H1648M{XibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTN{Lki2OVEh|ryPMVTTRW5ITVJ?
MKN1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rZU2lEPTB;M{SuNVExOSEQvF2=NF3JfppUSU6JRWK=
KYSE-450NUjvUHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnHbZBKSzVyPUO0MlY1PDRizszNNE\ueXJUSU6JRWK=
ES8NVP6PXNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3ueGRKSzVyPUO0Mlg6PzVizszNMXjTRW5ITVJ?
MS-1M4fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfnc4UxUUN3ME2zOE46PTV2IN88US=>NGOwOFdUSU6JRWK=
HOP-92NWP2VplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHr5RmtKSzVyPUO1MlkzPzdizszNMk\yV2FPT0WU
SKG-IIIaM2Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PEbWlEPTB;M{[uNlU3OSEQvF2=NVe0TJZ2W0GQR1XS
TE-11NYDVNXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7BTWM2OD1|Nj61NlQ{KM7:TR?=MXvTRW5ITVJ?
SK-NEP-1Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7OVopKSzVyPUO3MlY4PDRizszNMoLMV2FPT0WU
DBNX;COWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoW4TWM2OD1|Nz65NVg2KM7:TR?=NE[xN4JUSU6JRWK=
IA-LMNUf3O2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DXOmlEPTB;M{iuNFI{QSEQvF2=MkHjV2FPT0WU
COLO-829NF7GcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTZTWM2OD1|OD60NVU6KM7:TR?=NG\yWWdUSU6JRWK=
TGBC11TKBMkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPzWmhzUUN3ME2zPU4yPDB6IN88US=>MknxV2FPT0WU
CAL-51M4PBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTRyLkC2NVIh|ryPM2rEdnNCVkeHUh?=
NCI-H2228MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTRyLkO2OlIh|ryPM3\KUHNCVkeHUh?=
C32M4L1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTRyLkSwNlQh|ryPNGfIdlFUSU6JRWK=
KU-19-19MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXjTWM2OD12MD63Olg{KM7:TR?=MmPNV2FPT0WU
KNS-62MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTRyLkizPFEh|ryPMoPZV2FPT0WU
FADUNHnJO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknBTWM2OD12MT6yOVAzKM7:TR?=NIPiUJJUSU6JRWK=
CAL-33M2jXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LJZmlEPTB;NEKuOlc1QSEQvF2=NULMcmtpW0GQR1XS
CHP-134NV;DUWNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvoTWM2OD12Mj64OFk3KM7:TR?=MX;TRW5ITVJ?
HDLM-2M3L4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHmySXhKSzVyPUSyMlkxQDRizszNMVHTRW5ITVJ?
NBsusSRNVXZRmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTR|LkC3NlUh|ryPNUfkeoZRW0GQR1XS
SW954MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfMO20yUUN3ME20N{4yODV|IN88US=>NVPIbGdZW0GQR1XS
HCC1806Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHJUFdKSzVyPUSzMlQyOSEQvF2=Mn72V2FPT0WU
VMRC-RCZM2HYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\FR41KSzVyPUSzMlQ2QDZizszNNXnQboN6W0GQR1XS
A549MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;ITFJKSzVyPUSzMlk{OSEQvF2=MlHsV2FPT0WU
NKM-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFGxUoJKSzVyPUSzMlk2PThizszNMlPUV2FPT0WU
DMS-273Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W2bmlEPTB;NESuO|U3PyEQvF2=NVHUbFZsW0GQR1XS
TYK-nuM3PSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HHcGlEPTB;NEWuNVI{PCEQvF2=MVjTRW5ITVJ?
KALS-1NE\XOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTR3LkG0OkDPxE1?NF7SdmZUSU6JRWK=
A101DM2\rOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjTbIp6UUN3ME20OU41PDV4IN88US=>MVnTRW5ITVJ?
G-361MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTR4LkKxN|gh|ryPM2TNdnNCVkeHUh?=
KARPAS-299MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTkPItwUUN3ME20Ok4{PTF4IN88US=>NFHNc2lUSU6JRWK=
RS4-11M1LWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVG1Z3B{UUN3ME20Ok42PDJizszNNHe3eJpUSU6JRWK=
HT-1376NFvqR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\hfmlEPTB;NE[uO|QzPiEQvF2=NVjCWIxzW0GQR1XS
SK-N-ASM3TPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXzcVhKSzVyPUS2Mlc5OjJizszNNEKyOIJUSU6JRWK=
MG-63MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{[zb2lEPTB;NE[uPVA{PiEQvF2=NYPzW2tqW0GQR1XS
EPLC-272HNXX2Z5drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\hU2lEPTB;NE[uPVUxOyEQvF2=NFHnPIFUSU6JRWK=
BALL-1M1XKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fL[GlEPTB;NEeuPFMzKM7:TR?=NIrqTpVUSU6JRWK=
LCLC-97TM1M3j1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTR6LkKwNkDPxE1?M3TlR3NCVkeHUh?=
HO-1-N-1NFH3UGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1i2e2lEPTB;NEiuPVY4PiEQvF2=MVXTRW5ITVJ?
MFE-280M3:3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3v0c2lEPTB;NEmuOFYyPyEQvF2=NITLdnBUSU6JRWK=
NCI-H526MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGWxeZRKSzVyPUS5MlgyPjNizszNMWXTRW5ITVJ?
D-566MGM{nYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWO5U25MUUN3ME20PU46ODl4IN88US=>NWfvUHRLW0GQR1XS
BB30-HNCMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTR7Lkm0PVgh|ryPM{SzUXNCVkeHUh?=
SK-N-DZNEfVVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\iT2lEPTB;NUCuNFQ5OSEQvF2=MmHzV2FPT0WU
HepG2 M4\FTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrpNVDDqM7:TR?=NUS0UodwOjRiaB?=MWjicI9kc3NiU1OtTWlKOy2rbnT1Z4VlKFNicHjhd4Uh[XK{ZYP0NEexboszPTV{N{GyNy=>
HepG2 M4nEPWZ2dmO2aX;uJGF{e2G7MlraNVDDqM7:TR?=Ml7wNlQhcA>?M{m0ZpN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM>NXntVVZjOjV3MkexNlM>
KATO III NGnQPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7LNk42NzVxNz61JO69VQ>?M{ftb2ROW09?MVLlcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ?MU[yOFg1OTdzOB?=
hTCEpiMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP2PJcyOCEQvF2=NEXqfYlFVVORNWXWfGhyeHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1zNFvpNZgzPDN5MEizOS=>
MCF10AMkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TKZVExKM7:TR?=MkKwNlQhcA>?MVXEUXNQMoDZdI91\W62aXH0[ZMhfGinIHP5eI91d3irY3n0fUBw\iCJQR?=NFvQfoszPDF3MEW5OS=>
HL-60 M{XJfmZ2dmO2aX;uJGF{e2G7NYC3[5pxOTBizszNMWWwMlUhcA>?NYX1bmhbTE2VTx?=MlH6doVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLiM4n3SVI{QTN2NEGx
MCF-7M4XteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPnUnMyNTFyMN88US=>M1TOWVI1KGh?M1PMe2ZDWw>?MkXtbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>?Ml\kNlMyQDV|NEe=
HeLa Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHDNU0yODEQvF2=MlrqNlQhcA>?MUnGRnM>Ml7wbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>?MmnaNlMyQDV|NEe=
SH-SY5YMki1SpVv[3Srb36gRZN{[Xl?Mo[3NVDDqM7:TdMgNV3SZnFPOjRiaB?=MWPpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>?NX34Z4NROjJ4MkeyPVQ>
IMR-32NFXVVolHfW6ldHnvckBCe3OjeR?=NUnpe5lxOTEEoN88UeKhMYmyOEBpM{ezSolvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV|M2fhfFIzPjJ5Mkm0
A549M2r5b2Z2dmO2aX;uJGF{e2G7M4DscVExyqEQvF5CpC=>M{LI[lEhcA>?NXj0WYc3e3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=>NVLrbYxjOjJ3NUmzNlE>
T47D MoHkSpVv[3Srb36gRZN{[Xl?MUKyNOKhdU1?MoSwNlQhcA>?NFe1R3pFVVORNIXvUIZxemW4ZX70d{BKWi2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJGnPwkMQsR?=NH\UVIkzOTF2NEiwOS=>
A29 MEFMnXSSpVv[3Srb36gRZN{[Xl?M3HRPVExyqEQvF5CpC=>MV2xbC=>NIfSXHRjdG:la4RCpJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JIF1KFOnckS3N:KhMUiyNFA2Ozd6MR?=
MDA-MB-453 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfRXo9nPS12MDFOwG0>NUS1bnBIPzJiaB?=NIrjc25KSzVyIH;mJFExKM7:TR?=NFT3XoIzODB3M{e4NS=>
PC-3NH\jNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXL1VndiPS12MDFOwG0>MlvVO|IhcA>?NYDYXI5kUUN3MDDv[kAyOCEQvF2=MWmyNFA2Ozd6MR?=

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Purified enzyme assays ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.

Cell Assay: [1]

Cell lines U2OS cells
Concentrations 10 μM
Incubation Time 2 hours
Method U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.

Animal Study: [3]

Animal Models BALB/c nu/nu nude mice bearing LU1205 cells
Formulation
Dosages 10 μM
Administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hickson I, et al. Cancer Res. 2004, 64(24), 9152-9159.

[2] Soleimani R, et al. Aging. 2011, 3(8), 782-793.

view more

Chemical Information

Download KU-55933 (ATM Kinase Inhibitor) SDF
Molecular Weight (MW) 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 33 mg/mL (83.44 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO and 47.5% PEG300 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-morpholino-6-(thianthren-1-yl)-4H-pyran-4-one

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ATM/ATR Products

  • AZD6738

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • VE-822

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine Phosphate

    Chloroquine phosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Recently Viewed Items

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us